Literature DB >> 2471005

Central nervous system side effects of beta-adrenergic blocking agents with high and low lipid solubility.

J Conant1, R Engler, D Janowsky, A Maisel, E Gilpin, M LeWinter.   

Abstract

beta-adrenergic blocking agents have undesirable effects believed to be mediated through the central nervous system (CNS). If these effects are due to direct CNS action, less lipid soluble agents ought to have fewer effects. Accordingly, several formal psychological tests of items such as mood, motivation, and anxiety were used in a double-blinded crossover study in 17 hypertensive subjects taking equipotent beta blocking agents with high (propranolol) and low (atenolol) lipid solubility. Patients had less negative effects (p less than 0.05) on 12 of 21 items evaluated with atenolol compared to propranolol while peripheral beta blockade [beta 1, exercise heart rate (HR), and blood pressure (BP)] was equivalent. These results suggest that the mental changes which accompany beta blockade therapy are mediated directly in the CNS and that less soluble drugs can be expected to have fewer CNS effects.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2471005

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

1.  Risk of suicide in users of beta-adrenoceptor blockers, calcium channel blockers and angiotensin converting enzyme inhibitors.

Authors:  H T Sørensen; L Mellemkjaer; J H Olsen
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

Review 2.  Formulary considerations in selection of beta-blockers.

Authors:  K C Yedinak
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

3.  Beta-adrenergic receptors in the lateral nucleus of the amygdala contribute to the acquisition but not the consolidation of auditory fear conditioning.

Authors:  David E A Bush; Ellen M Caparosa; Anna Gekker; Joseph Ledoux
Journal:  Front Behav Neurosci       Date:  2010-10-26       Impact factor: 3.558

4.  Receptor occupancy in lumbar CSF as a measure of the antagonist activity of atenolol, metoprolol and propranolol in the CNS.

Authors:  T Kaila; R Marttila
Journal:  Br J Clin Pharmacol       Date:  1993-05       Impact factor: 4.335

5.  Cardiovascular drugs and the risk of suicide: a nested case-control study.

Authors:  Torbjörn Callréus; Ulla Agerskov Andersen; Jesper Hallas; Morten Andersen
Journal:  Eur J Clin Pharmacol       Date:  2007-03-20       Impact factor: 2.953

6.  Metoprolol-induced visual hallucinations: a case series.

Authors:  Jonathan A Goldner
Journal:  J Med Case Rep       Date:  2012-02-15

7.  Improvement in quality of life of Chinese chronic heart failure patients with neuropsychiatric complications over 12-months post-treatment with metoprolol.

Authors:  Ran Zhang; Jingjing Huang; Qiuhong Shu; Liyong Wu; Qian Zhang; Yong Meng
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.